FMP

FMP

Enter

REPL - Replimune Group, Inc...

photo-url-https://images.financialmodelingprep.com/symbol/REPL.png

Replimune Group, Inc.

REPL

NASDAQ

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

10.14 USD

-0.22 (-2.17%)

REPL Financial Statements

Year

2024

2023

2022

2021

Total Revenue

0

0

0

0

Cost of Revenue

2.65M

2.45M

4.58M

4.14M

Gross Profit

-2.65M

-2.45M

-4.58M

-4.14M

Operating Expenses

234.77M

174.17M

115.14M

77.15M

Research and Development

174.96M

126.53M

79.55M

56.75M

Selling, General & Administrative Expenses

59.81M

50.55M

38.77M

23.2M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

23.2M

Other Expenses

0

-5.68M

-1.06M

-665k

Operating Income

-234.77M

-177.08M

-118.31M

-79.95M

Total Other Income/Expenses Net

19.39M

3.08M

278k

-915k

Income Before Tax

-215.39M

-174M

-118.04M

-80.87M

Income Tax

408k

288k

1.16M

2.4M

Net Income

-215.79M

-174.28M

-118.04M

-80.87M

Basic EPS

-3.24

-2.99

-2.26

-1.75

EPS Diluted

-3.24

-2.99

-2.26

-1.75

Basic Average Shares

66.57M

58.21M

52.21M

46.25M

Diluted Average Shares

66.57M

58.21M

52.21M

46.25M

EBITDA

-230.2M

-170.3M

-114.41M

-76.48M

Retained Earning Schedule

Year

2024

2023

2022

2021

Retained Earnings (Previous Year)

-485.49M

-311.2M

-193.17M

-112.3M

Net Income

-215.79M

-174.28M

-118.04M

-80.87M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-701.28M

-485.49M

-311.2M

-193.17M

Other Distributions

-215.79M

-174.28M

-118.04M

-80.87M

PPE Schedule

Year

2024

2023

2022

2021

Gross PPE

52.35M

52.35M

55.58M

57.72M

Annual Depreciation

2.65M

2.45M

4.58M

4.14M

Capital Expenditure

-5.66M

-2.27M

-2.34M

-2.39M

Net PPE

55.36M

52.17M

53.34M

55.97M

Intangible and Goodwill Schedule

Year

2024

2023

2022

2021

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep